ASCO Backs Routine ESR1 Testing for Certain Breast Cancers

(MedPage Today) -- American Society of Clinical Oncology (ASCO) clinical practice guidelines now recommend routine testing for the emergence of ESR1 mutations at recurrence or progression on endocrine therapy -- with or without a CDK4/6 inhibitor...
Source: MedPage Today OB/GYN - Category: OBGYN Source Type: news